A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Mise à jour : Il y a 4 ans
Référence : NCT00413036

Femme et Homme

Extrait

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop


Critère d'inclusion

  • Lymphoma (non-Hodgkin's)


Liens